Skip to content

EASL 2025: hepatitis B

International EASL Current

EASL Clinical Practice Guidelines on the management of hepatitis B virus infection

European Association for the Study of the Liver. J Hepatol. 2025
DOI 10.1016/j.jhep.2025.03.018 · Summary checked against the source: 2026-11

Read or download the original

Replaces EASL 2017. Citations give the Oxford level of evidence and the strength (strong or weak) as written, and the page in the Journal of Hepatology article.

At a glance

  1. Assess every HBsAg-positive person: liver disease stage by non-invasive tests (elastography), abdominal ultrasound, and test for HDV, HCV and HIV. [strong · p. 6, 8]
  2. Treat chronic hepatitis B with HBV DNA ≥2,000 IU/mL and ALT >ULN and/or significant fibrosis. [LoE 1, strong · p. 13]
  3. Treat any cirrhosis with detectable HBV DNA, whatever the level or ALT. [LoE 3, strong · p. 13]
  4. HBeAg-positive or -negative chronic infection: individual decision; treat if raised HCC risk, extrahepatic disease, immunosuppression, or to prevent transmission. [p. 15, 17]
  5. Options: a nucleos(t)ide analogue (entecavir, tenofovir DF or alafenamide) or PEG-IFNα. [LoE 1, strong · p. 19]
  6. Pregnancy: tenofovir if HBV DNA ≥200,000 IU/mL, ideally started before the third trimester; breastfeeding is fine. [LoE 1, strong · p. 34]
  7. HCC surveillance: ultrasound every 6 months in at-risk patients, continued even after viral suppression or HBsAg loss. [LoE 2, strong · p. 31]

Diagnosis and staging

  • Baseline tests: HBsAg (quantitative), HBeAg and anti-HBe, HBV DNA, ALT; anti-HDV, anti-HCV and anti-HIV in everyone (strong). Anti-HBc IgM if acute hepatitis is suspected. [Table 5 · p. 6]
  • Assess the liver in every HBsAg-positive person: ultrasound at diagnosis and non-invasive fibrosis tests; biopsy only for uncertainty or discordant results. [strong · p. 8]
Liver stiffness (VCTE) Fibrosis
>7 kPa Significant (F2+)
>8 kPa Advanced (F3+)
>11 kPa Cirrhosis (F4)

Adapted from EASL 2025 Table 6 [p. 8]

Monitoring untreated patients: ALT and HBV DNA every 3–6 months in the first year, then every 6–12 months; HBsAg and (if HBeAg-positive) HBeAg and anti-HBe yearly; repeat non-invasive fibrosis tests. [strong · p. 9]

The disease phases keep the EASL names: HBeAg-positive chronic infection and chronic hepatitis, HBeAg-negative chronic infection and chronic hepatitis, and the HBsAg-negative phase (occult or resolved infection).

Who to treat

Strong recommendations [p. 13–17]

  • Chronic hepatitis B (HBeAg-positive or negative) with HBV DNA ≥2,000 IU/mL and ALT >ULN and/or significant fibrosis. [LoE 1, strong · p. 13]
  • Cirrhosis with any detectable HBV DNA. [LoE 3, strong · p. 13]
  • Chronic infection (HBeAg-positive or negative) with an increased HCC risk or extrahepatic manifestations. [LoE 3–4, strong · p. 15, 17]
  • Chronic infection before immunosuppression, or when immunocompromised. [LoE 2, strong · p. 15, 17]

Weak recommendations [p. 13–17]

  • Advanced fibrosis (≥F3 or LSM >8 kPa) with detectable HBV DNA, whatever the level. [LoE 5, weak · p. 13]
  • HBV DNA <2,000 with persistently raised ALT, after considering other liver diseases. [LoE 5, weak · p. 13]
  • Selected people with chronic infection, to prevent transmission. [LoE 3–4, weak · p. 15, 17]

Treatment

Nucleos(t)ide analogue (entecavir, TDF, TAF) PEG-IFNα
Route and duration Oral, long term (usually indefinite) Weekly injection, finite (48 weeks)
Effect Suppresses HBV DNA in almost everyone; HBsAg loss is rare Immune modulation; higher HBsAg loss in selected patients
Resistance Very low with entecavir and tenofovir None
Notes Check kidney function before and during; consider previous NA exposure Use predictors and stopping rules at weeks 12 and 24; not in decompensated cirrhosis

Adapted from EASL 2025 Tables 9–10 and recommendations [p. 19–29]

  • Goal: sustained HBV DNA suppression; ideal endpoint HBsAg loss ("functional cure"). [p. 12]
  • Cirrhosis: aim for undetectable HBV DNA by 12 months; otherwise adjust. Partial response or non-response: check adherence first. [LoE 3, strong; LoE 1, strong · p. 24]
  • Stopping NAs: stop after confirmed HBsAg loss. HBeAg-positive without advanced disease: may stop 12 months after HBeAg seroconversion with undetectable DNA, under close monitoring. Use HBsAg levels to select HBeAg-negative patients for stopping. [LoE 2 · p. 25]
  • De novo PEG-IFNα + NA combination isn't generally recommended; PEG-IFN add-on in selected HBeAg-negative patients on NA with low HBsAg. [LoE 2, weak · p. 29]

Special populations

Group Recommendation
Acute hepatitis B with impaired synthetic function NA, managed with a transplant centre (LoE 2, strong)
Pregnancy Continue tenofovir; switch entecavir or PEG-IFN to tenofovir. Untreated: treat for chronic hepatitis, HBV DNA ≥200,000 IU/mL, or HBeAg-positive where DNA testing isn't available. Start before the third trimester. Breastfeeding allowed (LoE 1–2, strong)
Newborn of HBsAg-positive mother Vaccine within 12 hours plus HBIG (LoE 1, strong)
HIV co-infection Treat HBV regardless of ALT or HBV DNA, with a tenofovir-containing ART; never stop it (LoE 2, strong)
HCV co-infection Treat HCV with DAAs; NA if the patient meets HBV criteria or to prevent reactivation (LoE 2, strong)
Hepatitis D PEG-IFNα or bulevirtide; NA if cirrhotic or HBV DNA ≥2,000; transplant assessment if decompensated (LoE 2–5)
Decompensated cirrhosis NA, no PEG-IFN, transplant assessment (LoE 1, strong)

Adapted from EASL 2025 [p. 34–38, 49]

Immunosuppression and reactivation

  • Test HBsAg and anti-HBc before any immunosuppression. [LoE 1, strong · p. 40]
  • HBsAg-positive, high or moderate risk: NA prophylaxis. Low risk: HBV DNA every 3 months, or prophylaxis if monitoring isn't feasible. [LoE 1–2, strong · p. 40]
  • HBsAg-negative, anti-HBc-positive: prophylaxis for high-risk immunosuppression (e.g. rituximab and other B-cell depletion); otherwise monitor. [LoE 2, strong · p. 40]
  • Continue prophylaxis 6–12 months after stopping immunosuppression, and ≥18 months after B-cell depleting therapy. [LoE 3, strong · p. 40]

Clinical pearls

  • Treat: DNA ≥2,000 + raised ALT and/or significant fibrosis; any cirrhosis with detectable DNA.
  • First line: entecavir, TDF or TAF (high barrier to resistance), or PEG-IFNα.
  • Pregnancy: tenofovir if DNA ≥200,000 IU/mL; birth-dose vaccine + HBIG within 12 h.
  • Rituximab carries the highest reactivation risk: give prophylaxis even if HBsAg-negative, anti-HBc-positive.
  • HCC surveillance: ultrasound 6-monthly.

Classes and levels of evidence

How EASL 2025 grades its recommendations. Adapted from EASL 2025 Tables 1–3 [p. 2–3]. Hover over any class or level cited on this page to see what it means.

Class Meaning Wording used
LoE 1 Systematic review of RCTs or n-of-1 trials (highest level)
LoE 2 Individual RCT, or observational study with dramatic effect
LoE 3 Non-randomised controlled cohort or follow-up study
LoE 4 Case series, case-control or historically controlled studies
LoE 5 Mechanism-based reasoning or expert opinion
A1 High-quality evidence (further research very unlikely to change confidence); strong recommendation
A2 High-quality evidence; weak recommendation
B1 Moderate-quality evidence (further research may change the estimate); strong recommendation
B2 Moderate-quality evidence; weak recommendation
C1 Low-quality evidence (any estimate of effect is uncertain); strong recommendation
C2 Low-quality evidence; weak recommendation
Level Meaning
Strong recommendation Wording: shall, should, is recommended (or should not). Based on evidence, consistency, risk–benefit, patient preference, ethics and feasibility
Weak or open recommendation Wording: can, may, is suggested (or may not)

Recent EASL guidelines rate evidence with Oxford Centre for Evidence-Based Medicine levels (1 strongest to 5) and grade each recommendation strong ("should", "is recommended") or weak/open ("can", "may", "is suggested"). Each also records the panel's consensus: strong consensus ≥95%, consensus 75–95%. EASL 2020 HCV instead uses evidence A–C with strength 1–2 (written A1, B2 and so on).